[Back to Documents Menu]
JONAS SALK PUBLICATIONS
139. Salk, J. --- Prospects for the control of AIDS through immunization of seropositive individuals. Nature 327(6122): 473-76, 1987.
141. Salk, J. --- Development and evaluation of a vaccine for human immunodeficiency virus (HIV) Infection. Ann. Int. Med.
143. Salk, J. and Gersten, M. J. --- Prophylactic and therapeutic immunization against AIDS: theoretical considerations underlying a modified non-infectious whole virus approach. In AIDS Vaccine: Research and Clinical Trials, S Putney and D. Bolognesi, eds. (New York: Marcel Dekker, Inc., 1990), pp. 265-275.
144. Salk, J. --- An envelope-deficient noninfectious HIV immunogen for studies on the prevention of HIV infection and/or disease. Human Retroviruses 119: 293-302, 1990.
147. Salk, J. --- The importance of HIV-specific CMI for the immunological control of HIV infection. Quatri¸me Colloque Des Cent Gardes, pp. 273-278, 1989.
148. Salk, J. --- Studies on HIV immunotherapy progress report. Quatri¸me Colloque Des Cent Gardes, pp. 313-317, 1989
150. Gibbs, Jr., C.J., Peters, R., Gravell, M., Johnson, B. K., Jensen, F. C., Carlo, D. J., and Salk, J. --- Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc. Natl. Acad. Sci. USA 88: 3348-3352, 1991.
151. Salk, J. --- Brightening prospects for the control of HIV/AIDS by immunological means. Cinquiˇme Colloque Des Cent Gardes, pp. 219-220, 1990.
154. Salk, J. --- Prospects for AIDS vaccines: the need for clinical trials in human populations. --- Vaccine 9(11): 791, 1991.
155. Levine, A., Henderson, B., Groshen, S., Munson, K., Allen, J., Carlo, D., Burnett, K., Jensen, F., Ferre, F., Trauger, R., Abrahamson, J., Gersten, M., and Salk, J. --- Immunization of HIV-infected individuals with inactivated HIV immunogen. Cinquiˇme Colloque Des Cent Gardes, pp. 247-250, 1990.
156. Slade, H., Turner, J., Abrams, C., Carlo, D., and Salk, J. --- Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study. AIDS Research and Human Retroviruses 8(8): 1329-31, 1992.
157. Salk, J. --- HIV Immunotherapy: what is the immunological objective to be achieved? Septi¸me Colloque Des Cent Gardes, pp. 283-84, 1992.
158. Atlan, H., Gertsten, M., Salk, P., and Salk, J. --- Can AIDS be prevented by T-cell vaccination? Immunology Today 14(5): 200-202, 1993.
159. Salk, J., Bretscher, P. A., Salk, P. L., Clerici, M., and Shearer, G. M. --- A strategy for prophylactic vaccination against HIV. Science 260: 1269-71, 1993.
160. Salk, J., Bretscher, P., Salk, P., Clerici, M., and Shearer, G. --- Protection from HIV Infection or AIDS? (response to Miedema, et al. letter). Science 262: 1074-76, 1993.
163. Salk, J. --- Immunotherapy of HIV/AIDS: approaches and criteria for effectiveness. Sixi¸me Colloque Des Cent Gardes, pp. 301-304, 1991.
166. Vaslin, B., Le Grand, R., Vogt, G., Benveniste, O., Gras, G., Roques, P., Stoeckel, P., Salk, P. L., Salk, J., and Dormont, D. --- Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection? Vaccine 12(12): 1132-40, 1994.
168. Atlan, H., Gersten, M. J., Salk, P. L., and Salk, J. --- Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention. Res. Immunol. 145: 165-83, 1994.
169. Salk, P. L. and Salk, J. --- Cell-mediated immunologic memory in prevention and treatment of HIV disease. Research in Immunology 145(8-9): 629-35, 1994. Overview of cytokine climate, CD8 T cells and therapies in AIDS, ibid., pp. 717-20.